Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Sep;8(1):e000745.
doi: 10.1136/bmjgast-2021-000745.

Review of exclusive enteral therapy in adult Crohn's disease

Affiliations
Review

Review of exclusive enteral therapy in adult Crohn's disease

Nikola Mitrev et al. BMJ Open Gastroenterol. 2021 Sep.

Abstract

Background: Exclusive enteral nutrition (EEN) is a potentially effective but underused therapy for Crohn's disease (CD) in adults. It is first-line induction treatment for paediatric patients but remains a second-line or third-line therapy in adults.

Objective: To analyse the evidence for EEN in adult patients with CD, and summarise this in a narrative review.

Methods: In April/May 2020 and July 2021, a literature search was performed using the Medical Subject Headings (MeSH) terms: 'Crohn's disease', 'CD', 'inflammatory bowel disease', 'IBD', 'exclusive enteral nutrition', 'enteral nutrition', 'EEN', in PubMed, Scopus, Cochrane. Additional studies were obtained from references of search result articles as well as general reading. Studies with adult patients with CD treated with EEN were selected. 79 articles of relevance were found. Where data in adults were lacking, data from paediatric studies as extrapolated with care.

Results: EEN in adult patients been shown to improve clinical, biomarker, endoscopic and radiologic measures of disease activity. EEN avoids the potential adverse effects of recurrent corticosteroids for induction such as metabolic derangements and opportunistic infections. EEN has also demonstrated benefits among adult patients with fistulising and stricturing CD. It may avoid surgery in such patients. Preoperative EEN has also been shown to reduce postoperative complications and recurrence. There appears to be benefits in combing EEN with antitumour necrosis factor agents, however, benefits of combination therapy with other biologics are less clear. A major drawback of EEN therapy in adults has been poor compliance. More palatable polymeric formulations improved patient education and dietitian support may overcome this. Evidence in adults is limited to small studies, often with suboptimal control arms and lack of blinding. Larger scale studies with improved study design are needed to confirm these beneficial effects.

Conclusion: Despite limitations in evidence EEN should be considered in treating adults with CD.

Keywords: crohn's disease; enteral nutrition; enteral/parenteral nutrition.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Figures

Figure 1
Figure 1
Mechanism showing the proposed effects of EEN. EEN improves outcomes in Crohn’s disease patients by potentially: (1) reducing antigens in whole foods and/ or direct anti-inflammatory effects, (2) improving micronutrient and macronutrient deficiencies and (3) correcting gut microbiota disturbances. EEN, exclusive enteral nutrition.

References

    1. Loftus EV. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology 2004;126:1504-17. 10.1053/j.gastro.2004.01.063 - DOI - PubMed
    1. Feuerstein JD, Cheifetz AS. Crohn disease: epidemiology, diagnosis, and management. Mayo Clin Proc 2017;92:1088–103. 10.1016/j.mayocp.2017.04.010 - DOI - PubMed
    1. Liu J, Kariyawasam V, Borody T. IDDF2018-ABS-0034 High age-specific prevalence of inflammatory bowel disease amongst the elderly in the city of canada bay area, sydney: a metropolitan, population-based study. Gut 2018;67:A35.
    1. Cheifetz AS. Management of active Crohn disease. JAMA 2013;309:2150–8. 10.1001/jama.2013.4466 - DOI - PMC - PubMed
    1. van Rheenen PF, Aloi M, Assa A, et al. . The medical management of paediatric Crohn's disease: an ECCO-ESPGHAN guideline update. J Crohns Colitis 2020. 10.1093/ecco-jcc/jjaa161. [Epub ahead of print: 07 Oct 2020]. - DOI - PubMed

Substances